Emergent BioSolutions

EBS · NYSE🇺🇸

Overview

Earnings Dividends Seasonality Metrics

Reported earnings about 1 month ago

Adjusted EBITDA Margin

Previous year: $99.5M

Previous year: $1.39B

-5.1%

Loading...

Emergent BioSolutions

Unlock previous datapoints

Upgrade

Emergent BioSolutions

Unlock previous datapoints

Upgrade

Emergent BioSolutions Revenue by Segment

Revenue by Segment

Naloxone Revenue

CapyFin.com

Anthrax MCM Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Smallpox MCM Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Other Products Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Services Revenue

CapyFin.com

Contracts and Grants Revenue

Unlock previous datapoints

Upgrade

CapyFin.com

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Key Statistics

Market Cap

$434M

P/E Ratio

3.50

Sector

N/A

Industry

N/A

52-Week High

$13.9

52-Week Low

$4.26

Adjusted EBITDA

$11.2M

Adjusted EBITDA Margin

8%

Gross Margin %

30%

Adjusted Gross Margin %

43%

Adjusted Net Loss

-$22.7M

Products

Get in Touch

Resources

Emergent BioSolutions

Emergent BioSolutions

Emergent BioSolutions

Emergent BioSolutions Revenue by Segment

Revenue by Segment

Naloxone Revenue

Anthrax MCM Revenue

Smallpox MCM Revenue

Other Products Revenue

Services Revenue

Contracts and Grants Revenue

Revenue & Expenses

Historical Earnings Impact

Avg. Return Before/After Earnings

Key Statistics